Search results

Summaries of the best available evidence for selected medicines that are considered to be of significance to the NHS.

An approximate guide to the timings for the development of a piece of HealthTech guidance.

Our Medical Technologies Evaluation Programme (MTEP) considers technologies that could offer benefits to patients and the health and social care system over current practice.

Our Medical Technologies Evaluation Programme (MTEP) evaluates new HealthTech.

We want you to be involved in our work - whether you’re commenting on our draft recommendations, taking part in guidance development or attending a committee meeting, your voice is important to us.

Clarification on demonstrating patient access to medicines and treatments recommended by NICE Technology Appraisal (TA) or Highly Specialised Technologies (HST) guidance.

NICE has a key role in UK licensing and the evaluation of and access to new and innovative products for the health system.

Home What NICE does Our guidance About technology appraisal guidance {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":

Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.

Our modular updates framework ensures flexibility and consistency in updating our manuals and helps prioritise important updates.

Data on the recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.

NICE priority methodological research areas.

Check our list of appointed suppliers to find out which knowledge resources and services they can offer.

Home Implementing NICE guidance Cost saving, resource planning and audit {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElemen

Smoking cessation positively impacts all 5 clinical areas identified by Core20PLUS5 adults.